ICER publishes evidence report on additive cardiovascular disease therapies

12 September 2019 - Pricing of rivaroxaban and icosapent ethyl aligns well with treatments’ benefits for patients; expert roundtable will discuss ...

Read more →

ICER releases draft evidence report on diabetes therapies

11 September 2019 - Public comment period now open until 8 October 2019; Requests to make oral comment during public meeting ...

Read more →

ICER's blasted pharma pricing for years, but now drug makers are 'rolling up their sleeves' to cooperate

10 September 2019 - Sanofi and Regeneron's next-gen cholesterol drug Praluent never lived up to early expectations, and its price ...

Read more →

As value assessment frameworks evolve, are they finally ready for prime time?

9 September 2019 - Value assessment frameworks have emerged as tools to assist health care decision makers in the United States ...

Read more →

Achieving appropriate model transparency: challenges and potential solutions for making value‑based decisions in the United States

5 September 2019 - Transparency in decision modeling remains a topic of rigorous debate among healthcare stakeholders, given tensions between the ...

Read more →

ICER to assess treatments for cystic fibrosis

6 September 2019 - Report will be subject of California Technology Assessment Forum meeting in April 2020; open Input now being ...

Read more →

ICER to assess treatments for ulcerative colitis

6 September 2019 - Report will be subject of CTAF meeting in June 2020; open Input now being accepted until 24 ...

Read more →

ICER posts draft scoping document for the assessment of treatments for Sickle cell disease

30 August 2019 - Document open to public comment until 20 September 2019. ...

Read more →

ICER Proposes Updates to 2020 Value Assessment Framework Methods and Procedures

21 August 2019 - Reflecting experience with current framework, benchmarking with other HTA groups, and public input, proposals include new emphasis ...

Read more →

ICER's value framework and patient feedback: Q&A with Steve Pearson

15 August 2019 - ICER invites all patient organizations and the general public to attend a webinar to learn more ...

Read more →

ICER issues final report and policy recommendations regarding treatments for Duchenne muscular dystrophy

15 August 2019 - Public meeting reveals tensions inherent around high-priced treatments that lack adequate evidence of efficacy. ...

Read more →

ICER to assess treatments for sickle cell disease

9 August 2019 - Report will be subject of New England CEPAC meeting in March 2020; open Input now being ...

Read more →

ICER issues statement regarding manufacturer's manipulation of data from animal testing of Zolgensma

7 August 2019 - Yesterday afternoon, the FDA announced that Novartis informed the agency in June of a data manipulation ...

Read more →

A watchdog group sets aside emotions to assess drugs’ value. Patients say their lives are more than a number.

2 August 2019 - Health economists walk a precarious tightrope: their analyses are quantitative and, presumably, emotion-free. But health care ...

Read more →

ICER seeks public comment on proposed methods adaptations for assessments of potential cures and other transformative therapies

6 August 2019 - Proposed adaptations help manage increased uncertainty, capture new value dimensions for appraisal committee voting, and adopt a ...

Read more →